

PHARMANUTRA OBTAINS THE SOLID IRON PATENT FOR THE USA After Europe, the intellectual property rights of the patent expiring in 2033 are now acknowledged in the United States

Pisa, 5th November 2019 – A fundamental new strategic corporate asset joins those already held by PharmaNutra S.p.A. (*Aim Italia - Ticker PHN*), a nutraceutical company that leads the market in the oral iron products sector.

The Company founded by the brothers Andrea and Roberto Lacorte in 2003 has now also received the Solid Iron patent concession (number 10,183,077) for the United States. Applied for in July 2013, the patent will be valid for 20 years, thus expiring in 2033. Alongside the European one held by PharmaNutra since January 2019.

The company's flagship product, SiderAL[®], is based on the Sucrosomial[®] Technology of the PharmaNutra Group, representing the result of years of research to overcome the limits and problems caused by daily administration of traditional oral iron, with its reduced absorption and limited gastrointestinal tolerability. The term "sucrosomial" comes from the fact that the iron is conveyed using a unique technology called sucrosomial that helps preserve, transport, protect and absorb the iron. Thanks to the high absorption and tolerability level, the result of a unique mechanism patented by PharmaNutra, Sucrosomial[®] iron-based supplements are acknowledged internationally as the sector's most effective and innovative, by both the medical-scientific community and by consumers.

The patent having been granted in the USA is a decisive asset for being able to enter a strategic market in both size and growth potential. Considering that the US pharmaceutical market is estimated at about \$ 484.9 billion, with increases of 4-7% expected for the 2019-2023 five-year period (source Report Iqvia "The Global Use of Medicine in 2019 and Outlook to 2023"), resulting in a high active principles import rate to respond to the high internal demand.

Andrea Lacorte, President of PharmaNutra S.p.A., said: "Obtaining the patent for the United States opens the doors to one of the world's most important markets, with very rigid rules, proof of the extreme scientific validity and unique properties of our Sucrosomial[®] Iron. A certification that enables us to increase our distribution potential in a fundamental country for the international growth of the PharmaNutra Group".

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 91 of them published and with more than 6000 subjects treated with the supplements. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. <http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfsim.com

Press Office

Spriano Communication&Partners
Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com